Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) reached a new 52-week low on Wednesday . The company traded as low as $8.03 and last traded at $8.41, with a volume of 127832 shares traded. The stock had previously closed at $8.15.
A number of research analysts have weighed in on KNSA shares. Zacks Investment Research upgraded Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Friday, August 16th. ValuEngine raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wedbush reissued a “buy” rating on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, JMP Securities dropped their price target on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $26.50.
The business has a 50-day moving average price of $9.68 and a 200 day moving average price of $13.90. The stock has a market capitalization of $505.76 million, a P/E ratio of -2.41 and a beta of -1.33.
Several institutional investors and hedge funds have recently modified their holdings of the company. First Manhattan Co. boosted its position in shares of Kiniksa Pharmaceuticals by 68.3% in the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock worth $866,000 after purchasing an additional 25,970 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals by 195.8% in the 2nd quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock worth $5,041,000 after purchasing an additional 246,442 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth approximately $474,000. Morgan Stanley lifted its position in Kiniksa Pharmaceuticals by 54.2% in the 2nd quarter. Morgan Stanley now owns 60,098 shares of the company’s stock valued at $814,000 after acquiring an additional 21,130 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Kiniksa Pharmaceuticals by 14.4% in the 2nd quarter. BlackRock Inc. now owns 1,107,091 shares of the company’s stock valued at $14,990,000 after acquiring an additional 139,072 shares in the last quarter. 30.22% of the stock is currently owned by hedge funds and other institutional investors.
Kiniksa Pharmaceuticals Company Profile (NASDAQ:KNSA)
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Read More: Market Perform
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.